News und Analysen

In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), and other semiconductor stocks. To learn more, check out the short video, consider

This year has offered no shortage of market-moving headlines shaping investor sentiment. Mixed job reports, new tariffs fueling turbulence in U.S. trade policy, and ongoing uncertainty around

Viking Therapeutics (NASDAQ: VKTX) announced trial results for its weight loss pill that disappointed stock market investors.

*Stock prices used were the afternoon prices of Aug. 24, 2025. The

Telecom giant AT&T (NYSE: T) struck a deal with EchoStar on Tuesday to acquire wireless spectrum licenses that cover nearly ever market across the U.S. The company will pay $23 billion for 30 MHz of

U.S. equity markets rose broadly on Tuesday as optimism over monetary policy, upbeat corporate news, and anticipation of Nvidia (NASDAQ: NVDA)'s earnings propelled gains. The S&P 500 added 0.41%

When it comes to growth stocks, you have to understand the risks going in. But there are three growth stocks that I have strong convictions about, and they could produce huge returns for investors.

Viking Therapeutics (NASDAQ: VKTX) delivered one of the most anticipated obesity readouts of the year -- and Wall Street promptly panicked. Shares plummeted 40% after the company released Phase 2

Vertex Pharmaceuticals (NASDAQ: VRTX) is usually a market-beater, but it hasn't been so over the past year. The company's shares are down 18% over the trailing-12-month period due to a combination

Viking Therapeutics (NASDAQ: VKTX) and Regeneron Pharmaceuticals (NASDAQ: REGN) have faced challenges this year that have sunk their stock prices. The former is down by 37% this year, while the

Amid competition in the cruise line industry, investors seem to have overlooked Royal Caribbean (NYSE: RCL). The larger market share of Carnival and the relatively recent IPO of Viking Holdings seem

How does getting paid to own a stock sound to you? That's exactly what dividends do. Even if you don't need extra income, reinvesting dividends can significantly increase the total returns you

Shares in Viking Therapeutics (NASDAQ: VKTX) crashed by 35.9% in the week to Friday morning. The decline comes in a week when the company released its top-line results from its phase 2 trial of its

Nvidia (NASDAQ: NVDA) closed down 0.2% at $174.98 on Thursday, with trading volume of 135 million shares, below its three-month average of 181 million. The modest decline contrasted with weakness in

As of Aug. 20, shares of Viking Therapeutics (NASDAQ: VKTX) fell a whopping 39.2% from their previous close on Tuesday, Aug. 19. Investors were reacting to new clinical trial results regarding its

Dividend Champions are known for their reliability. These companies have raised their dividends annually for at least 25 years. Some remain overlooked by investors because they don't need to be in

Shares of Viking Therapeutics (NASDAQ: VKTX) rose by almost 10% at 11 a.m. ET today. This follows a significant fall the previous day on the release of its eagerly awaited top-line results from a

Image source: The Motley Fool.

Wednesday, August 20, 2025 at 10 a.m. ET

Chairman, President, and Chief Executive Officer — Vincent Roche

Continue reading

Source Fool.com

What's better than a stock that pays great dividends? How about one that's also a bargain? Granted, most strong dividend stocks aren't available at a discount in the current high-flying market

Vertex Pharmaceuticals (NASDAQ: VRTX) has been a top pharma stock in recent years. It has been generating strong revenue growth while also building out its portfolio of drugs, expanding its growth

Nvidia (NASDAQ: NVDA) shares fell 3.5% on Tuesday, closing at $175.64, as tech stocks broadly pulled back following a recent rally. The chipmaker traded 183 million shares, just above its

Viking Therapeutics (NASDAQ: VKTX) stock collapsed in morning trading Tuesday, down more than 40% after reporting mixed results for its GLP-1 weight loss pill VK2735. As Viking shares plummet

Viking Therapeutics (NASDAQ: VKTX) stock collapsed on Tuesday, down 41.4% through 10:25 a.m. ET after reporting what pharmaceutical analysts are calling "mixed results" for its new GLP-1 weight loss

Viking Holdings(NYSE:VIK) reported second-quarter 2025 earnings on August 19, 2025, achieving 18.5% year-over-year revenue growth to $1.9 billion, an adjusted EBITDA increase of 28.5% to $633

Finding a high-yielding stock that is safe to hang on to can be a rarity. When yields get high (e.g., more than 5%), usually there's a reason behind it. And investors are often hesitant to invest in

Space and defense stock Voyager Technologies (NYSE: VOYG) took off like a rocket packed with fuel on Monday. The company's shares gained more than 13% in value after it divulged an investment into